1. Home
  2. IART vs ATAI Comparison

IART vs ATAI Comparison

Compare IART & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Integra LifeSciences Holdings Corporation

IART

Integra LifeSciences Holdings Corporation

HOLD

Current Price

$14.92

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

ATAI

ATAI Life Sciences N.V.

HOLD

Current Price

$4.38

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IART
ATAI
Founded
1989
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.3B
IPO Year
1996
2025

Fundamental Metrics

Financial Performance
Metric
IART
ATAI
Price
$14.92
$4.38
Analyst Decision
Hold
Strong Buy
Analyst Count
7
8
Target Price
$14.33
$15.88
AVG Volume (30 Days)
1.1M
4.3M
Earning Date
05-05-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$4,089,000.00
Revenue This Year
$4.39
N/A
Revenue Next Year
$3.40
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1227.60
52 Week Low
$8.70
$2.00
52 Week High
$16.42
$6.73

Technical Indicators

Market Signals
Indicator
IART
ATAI
Relative Strength Index (RSI) 67.71 57.81
Support Level $12.64 $3.46
Resistance Level $16.35 $4.58
Average True Range (ATR) 0.90 0.23
MACD 0.10 0.01
Stochastic Oscillator 84.02 81.82

Price Performance

Historical Comparison
IART
ATAI

About IART Integra LifeSciences Holdings Corporation

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.

About ATAI ATAI Life Sciences N.V.

AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.

Share on Social Networks: